Page 6 - Top Ten Tips Palliative Care Clinicians Should Know About Medical Cannabis

6 BRISCOE ET AL.

23. Johnson JR, Burnell-Nugent M, Lossignol D, et al.: Mul- 39. Gurney J, Shaw C, Stanley J, et al.: Cannabis exposure and
ticenter, double-blind, randomized, placebo-controlled, risk of testicular cancer: A systematic review and meta-
parallel-group study of the efficacy, safety, and tolerability analysis. BMC Cancer 2015;15:897.
of THC:CBD extract and THC extract in patients with in- 40. Tetrault JM, Crothers K, Moore BA, et al.: Effects of
tractable cancer-related pain. J Pain Symptom Manage marijuana smoking on pulmonary function and respiratory
2010;39:167–179. complications: A systematic review. Arch Intern Med
24. Musty RE, Rossi R: Effects of smoked cannabis and oral 2007;167:221–228.
D9-tetrahydrocannabinol on nausea and emesis after cancer 41. Mittleman MA, Lewis RA, Maclure M, et al.: Triggering
chemotherapy: A review of state clinical trials. J Cannabis myocardial infarction by marijuana. Circulation 2001;103:
Ther 2001;1:29–56. 2805–2809.
25. Chang AE, Shiling DJ, Stillman RC, et al.: A prospective 42. Sidney S: Cardiovascular consequences of marijuana use. J
evaluation of delta-9-tetrahydrocannabinol as an antiemetic Clin Pharmacol 2002;42(S1):64S–70S.
in patients receiving adriamycin and cytoxan chemother- 43. Galli JA, Sawaya RA, Friedenberg FK: Cannabinoid hy-
apy. Cancer 1981;47:1746–1751. peremesis syndrome. Curr Drug Abuse Rev 2011;4:241–249.
26. Chang AE, Shiling DJ, Stillman RC, et al.: Delta-9- 44. Kedzior KK, Laeber LT: A positive association between
tetrahydrocannabinol as an antiemetic in cancer patients anxiety disorders and cannabis use or cannabis use disor-
receiving high-dose methotrexate: A prospective, random- ders in the general population—A meta-analysis of 31
ized evaluation. Ann Intern Med 1979;91:819–824. studies. BMC Psychiatry 2014;14:136.
Downloaded by Gothenburg University Library from www.liebertpub.com at 01/15/19. For personal use only.
27. Smith LA, Azariah F, Lavender VTC, et al.: Cannabinoids 45. Borges G, Bagge CL, Orozco R: A literature review and
for nausea and vomiting in adults with cancer receiving meta-analyses of cannabis use and suicidality. J Affect
chemotherapy. Cochrane Database Syst Rev 2015;(11): Disord 2016;195:63–74.
CD009464. 46. Broyd SJ, van Hell HH, Beale C, et al.: Acute and chronic
28. Geffrey AL, Pollack SF, Bruno PL, Thiele EA: Drug-drug effects of cannabinoids on human cognition—A systematic
interaction between clobazam and cannabidiol in children review. Biol Psychiatry 2016;79:557–567.
with refractory epilepsy. Epilepsia 2015;56:1246–1251. 47. Wilkinson ST, Radhakrishnan R, D’Souza DC: Impact of
29. Zendulka O, Dovrte ˇlova ´ G, Noskova ´ K, et al.: Cannabi- cannabis use on the development of psychotic disorders.
noids and cytochrome P450 interactions. CDM 2016;17: Curr Addict Rep 2014;1:115–128.
206–226. 48. Marconi A, Di Forti M, Lewis CM, et al.: Meta-analysis of
30. Russell C, Rueda S, Room R, et al.: Routes of adminis- the association between the level of cannabis use and risk
tration for cannabis use–basic prevalence and related health of psychosis. Schizophr Bull 2016;42:1262–1269.
outcomes: A scoping review and synthesis. Int J Drug 49. Karler R, Turkanis S: The cannabinoids as potential anti-
Policy 2018;52:87–96. epileptics. J Clin Pharmacol 1981;21(S1):437S–448S.
31. Burstein O, Shoshan N, Doron R, Akirav I: Cannabinoids 50. Sulak D, Saneto R, Goldstein B: The current status of ar-
prevent depressive-like symptoms and alterations in BDNF tisanal cannabis for the treatment of epilepsy in the United
expression in a rat model of PTSD. Prog Neuropsycho- States. Epilepsy Behav 2017;70(Part B):328–333.
pharmacol Biol Psychiatry 2018;84(Part A):129–139. 51. Gloss D, Vickrey B: Cannabinoids for epilepsy. Cochrane
32. Loflin MJ, Babson KA, Bonn-Miller MO: Cannabinoids as Database Syst Rev 2014;69:14–25.
therapeutic for PTSD. Curr Opin Psychol 2017;14:78–83. 52. Devinsky O, Marsh E, Friedman D, et al.: Cannabidiol in
33. Narang S, Gibson D, Wasan AD, et al.: Efficacy of dro- patients with treatment-resistant epilepsy: An open-label
nabinol as an adjuvant treatment for chronic pain patients interventional trial. Lancet Neurol 2016;15:270–278.
on opioid therapy. J Pain 2008;9:254–264. 53. Devinsky O, Cross JH, Laux L, et al.: Trial of cannabidiol
34. Frank B, Serpell MG, Hughes J, et al.: Comparison of an- for drug-resistant seizures in the Dravet syndrome. N Engl J
algesic effects and patient tolerability of nabilone and di- Med 2017;376:2011–2020.
hydrocodeine for chronic neuropathic pain: Randomised, 54. Commissioner OOT: Press announcements—FDA ap-
crossover, double blind study. BMJ 2008;336:199–201. proves first drug comprised of an active ingredient derived
35. van den Elsen GAH, Ahmed AIA, Lammers M, et al.: Ef- from marijuana to treat rare, severe forms of epilepsy. 2018.
ficacy and safety of medical cannabinoids in older subjects: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements
A systematic review. Ageing Res Rev 2014;14:56–64. /ucm611046.htm
36. Strasser F, Luftner D, Possinger K, et al.: Comparison of 55. Gaston TE, Bebin EM, Cutter GR, et al.: Interactions be-
orally administered cannabis extract and delta-9- tween cannabidiol and commonly used antiepileptic drugs.
tetrahydrocannabinol in treating patients with cancer- Epilepsia 2017;58:1586–1592.
related anorexia-cachexia syndrome: A multicenter, phase 56. Rogeberg O, Elvik R: The effects of cannabis intoxication
III, randomized, double-blind, placebo-controlled clinical on motor vehicle collision revisited and revised. Addiction
trial from the Cannabis-In-Cachexia-Study-Group. J Clin 2016;111:1348–1359.
Oncol 2006;24:3394–3400. 57. Hartman RL, Huestis MA: Cannabis effects on driving
37. Zhang LR, Morgenstern H, Greenland S, et al.: Cannabis skills. Clin Chem 2013;59:478–492.
smoking and lung cancer risk: Pooled analysis in the In- 58. Drug Impaired Driving: Governors Highway Safety Asso-
ternational Lung Cancer Consortium. Int J Cancer 2015; ciation. www.ghsa.org/state-laws/issues/drug%20impaired
136:894–903. %20driving (Last accessed October 6, 2018).
38. Joshi M, Joshi A, Bartter T: Marijuana and lung diseases. 59. American Medical Association: Cannabis Legalization for
Curr Opin Pulm Med 2014;20:173–179. Medicinal Use D-95.969. 2018.